Prabotulinumtoxin longer duration formulation first interim analysis

Dr Rui AVELAR

DaxibotulinumtoxinA for injection: the new FDA-approved long lasting botulinum toxin formulation

Conor GALLAGHER

LetibotulinumtoxinA: what’s new 1 year after approval?

Dr Michael CECERLE

Toxins overview: 2023 update

Dr Philippe PICAUT

ET-01 – A phase 2b topical botulinum product candidate

Jon EDELSON

Ear challenge with ELBAF

Dr Aurore LE GUERN

Role of VZV in segmental vitiligo pathogenesis

Prof Laila BENZEKRI

Vitiligo: PUVA, laser, or JAK inhibitors?

Dr Amr RATEB SAID

Dermoscopic criteria used to differentiate vitiligo from other hyperpigmented skin lesions

Prof Manal BOSSEILA

Vitiligo and JAK inhibitors

Prof Pierre - Andre BECHEREL

Current vitiligo treatments in 2024

Dr Albert WOLKERSTORFER

Segmental vitiligo with topical ruxolitinib and 308 nm monochromatic excimer light

Dr Cheryl M BURGESS

Clinical uses of botulinum toxin

Dr Meelad HABIB

Clinical anatomy for off-label botulinum toxin type A

Dr Alessio REDAELLI

Unconventional approaches for hidradenitis suppurativa: from laser to botulinum toxin

Dr Claudio MARASCA